Hebrew University researchers used plan to produce an effective anti-malaria drug; combating malaria is one of the eight Millennium Development Goals.
A genetically engineered form of artemisinin, a natural compound that produces large quantities of the anti-malaria drug - was announced Sunday by the Yissum Research Development Company – the Hebrew University of Jerusalem’s technology transfer company. The biosynthesis method - a novel way of producing Artemisia annua, which is naturally produced by sweet wormwood plants - was developed by Prof. Alexander Vainstein and the research was published as a letter in the latest issue of the journal Nature Biotechnology.
Combating malaria is one of the eight Millennium Development Goals described in the UN Millennium Declaration signed by all UN members 11 years ago. An important way to control the deadly parasitic disease that affects mostly the Third World is prompt and effective treatment with artemisinin-based combination therapies.
But low-cost artemisininbased drugs are in short supply because of the high cost of obtaining the natural or chemically synthesized drug. Despite extensive efforts made in the last decade in metabolic engineering of the drug in both microbial and heterologous plant systems, no one has been able to produce artemisinin itself.
Malaria, caused by the Plasmodium parasite, is transmitted via mosquitoes. Symptoms include fever, headache and vomiting, and they usually appear between 10 and 15 days after the mosquito bite. If left untreated, malaria can quickly become life threatening by disrupting the blood supply to vital organs. Over three billion people are at risk of malaria, and about 250 million new malaria cases occur each year, causing nearly a million deaths, mostly of people living in poor countries.
Vainstein and graduate student Moran Farhi developed genetically engineered tobacco plants carrying genes encoding the entire biochemical pathway needed for producing artemisinin. In light of tobacco’s high biomass and rapid growth, this invention will enable a cheap production of large quantities of the drug, paving the way for the development of a sustainable plant-based platform for the commercial production of an antimalarial drug, said Yissum, which patented it and is now seeking a partner for its further development.
Yissum CEO Yaacov Michlin said Vainstein’s technology provides for the first time, the opportunity for manufacturing affordable artemisinin by using tobacco plants.
“We hope this invention will eventually help control this prevalent disease, for the benefit of many millions of people around the globe and in particular in the developing world.”
By JUDY SIEGEL